About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Imago BioSciences Appoints Wan-Jen Hong, M.D., as Chief Medical Officer

Appointment reflects commitment to advance the Imago clinical pipeline

Imago BioSciences, Inc. (“Imago”), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced the appointment of Wan-Jen Hong, M.D., as chief medical officer. Dr. Hong will be responsible for leading the clinical development of the Imago pipeline of therapies targeting LSD1 in various cancers and other bone marrow diseases. Dr. Hong joins Imago from Genentech, where she served as Group Medical Director in their late-stage clinical development group.

“I am delighted to welcome Wan-Jen to our team, and we look forward to her leadership and guidance as we continue to advance our pipeline of therapies to treat diseases of the bone marrow,” said Hugh Young Rienhoff, Jr., M.D., chief executive officer of Imago BioSciences. “Wan-Jen’s extensive background in hematology and oncology will be a strong asset for Imago as we complete our Phase 2 studies of bomedemstat for the treatment of myeloproliferative disorders, including essential thrombocythemia and myelofibrosis.”

Dr. Hong is a physician scientist with more than 10 years of clinical and scientific expertise in hematology and oncology disorders. In her most recent role at Genentech, Dr. Hong worked on the development of several molecules across multiple indications in hematology and oncology, and played a leading role in the indication expansion of venetoclax (VENCLEXTA®) in acute myeloid leukemia. Prior to Genentech, Dr. Hong was a clinical instructor in hematology at the Stanford University School of Medicine and is currently an adjunct clinical faculty member in its Division of Hematology. She earned a bachelor’s degree in chemical engineering and biology from Massachusetts Institute of Technology and completed both her medical doctorate and clinical training, including a hematology/oncology fellowship, at Stanford University.

“Imago has generated significant data on its lead asset bomedemstat in several indications,” said Dr. Wan-Jen Hong, chief medical officer, Imago BioSciences. “Patients with myeloproliferative neoplasms and other hematological disorders continue to face significant challenges despite the current treatments. I am excited to work with the Imago team to develop bomedemstat as a new treatment option for patients with unmet medical needs.”

About Imago BioSciences

Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. Imago is focused on improving the quality and length of life for patients with cancer and bone marrow diseases. Bomedemstat, an orally available, small molecule inhibitor of LSD1, is the lead product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (ET) and myelofibrosis (MF). Bomedemstat has U.S. FDA Orphan Drug and Fast Track Designation for the treatment of ET and MF, Orphan Drug Designation for treatment of AML, and PRIME designation by the European Medicines Agency for the treatment of MF. Imago is backed by leading private, crossover and strategic investors including a fund managed by Blackstone Life Sciences, Frazier Healthcare Partners, Omega Funds, Farallon Capital Management, L.L.C., funds and accounts advised by T. Rowe Price Associates, Inc., and funds and accounts managed by Blackrock Advisors, LLC. The company is based in South San Francisco, California.

To learn more, visit: www.imagobio.com, www.myelofibrosisclinicalstudy.com, www.etclinicalstudy.com and follow us on Twitter @ImagoBioRx, Facebook, LinkedIn and YouTube.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.